Skip to main content
SpringerLink
Log in

Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine

  • Published:
AAPS PharmSci Aims and scope Submit manuscript

Abstract

It has been reported that the toxicity of carmustine (BCNU) cyclophosphamide (CY)/etoposide regimen (when BCNU is split into 4 doses) is less than that of BCNU/CY/cisplatin regimen (when the same amount of BCNU is administered as a single dose). We hypothesized that this might in part be due to the inhibition of aldehyde dehydrogenase 1 (ALDH1) by BCNU or its degradation product, 2-chloroethyl isocyanate, which is likely to be more pronounced at the higher BCNU dose. The effects of BCNU and 2-chloroethyl isocyanate on the formation of carboxyethylphosphoramide mustard (CEPM) from 4-hydroxycyclophosphamide (HCY) was evaluated in human liver cytosol incubations. We found that CEPM formation from HCY was inhibited strongly by BCNU and weakly by 2-chloroethyl isocyanate. The mechanism of inhibition of ALDH1 activity by BCNU was elucidated using indole-3-acetaldehyde (IAL) as the probe substrate in ALDH1 prepared from human erythrocytes. BCNU was a competitive inhibitor of ALDH1 activity with a Ki of 1.95 μM. The inhibition was independent of preincubation time and reversible by dialysis. The calculated %inhibition of ALDH1 activity by acrolein and BCNU in patients receiving BCNU in 4 split doses with CY was 81%, and it increased to 92% in single dose BCNU regimen. Thus, the calculation indicates that residual operating ALDH1 activity is halved in the presence of single-dose BCNU compared to split-dose BCNU. The inhibition of ALDH1 may contribute to the observed lower incidence of toxicity when BCNU was split into 4 doses compared with single dose and coadministered with CY although dose-dependent effects of BCNU on glutathione and glutathione reductase are also likely to contribute.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CY:

cyclophosphamide

BCNU:

carmustine

HCY:

4-hydroxycyclophosphamide

CEPM:

carboxyethylphosphoramide mustard

ALDH1:

aldehyde dehydrogenase 1

References

  1. Ren, S., Yang, J.-S., Kalhorn, T. F., and Slattery, J. T. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res. 57, 4229–4235, 1997.

    CAS  PubMed  Google Scholar 

  2. Chang, T. K. H., Yu, L., Goldstein, J. A., and Waxman, D. J. Identification of the polymorphically expressed CYP21 and the wild-type CYP2C9-ILE359 allele as low-K-m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics, 7: 211–221, 1997.

    Article  CAS  PubMed  Google Scholar 

  3. Dockham, P. A., Lee, M.-O., and Sladek, N. E. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol., 43: 2453–2469, 1992.

    Article  CAS  PubMed  Google Scholar 

  4. Parekh, H. K. and Sladek, N. E. NADPH-dependent enzymecatalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Biochem. Pharmacol., 46: 1043–1052, 1993.

    Article  CAS  PubMed  Google Scholar 

  5. Sladek, N. E. Metabolism and pharmacokinetics of cyclophosphamide and related oxazaphosphorines. In: G. Powis (ed.) Anticancer Drugs: Reactive Metabolism and Drug Interactions, pp. 79–156, New York: Pergamon Press Ltd., 1994.

    Google Scholar 

  6. Devita, V. T., Hellman, S., and Rosenberg, S. A. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott, 1985.

    Google Scholar 

  7. Colvin, M. and Brundrett, R. Chemical decomposition of chloroethylnitrosoureas. In: A. W. Prestakyo, S. T. Crooke, S. K. Baker, and P. S. Schein (eds.), Nitrosoureas, pp. 43–49. New York. Academic Press, 1981.

    Chapter  Google Scholar 

  8. Ludlum, D. B. and Tong, W. P. Modification of DNA and RNA bases. In: A. W. Prestakyo, S. T. Crooke, S. K. Baker, and P. S. Schein (eds.), Nitrosoureas, pp. 85–94. New York: Academic Press, 1981.

    Chapter  Google Scholar 

  9. Ayash, L. J., Hunt, M., Antman, K., Nadler, L., Wheeler, C., Takvorian, T., Elias, A., Antin, J. H., Greenough, T., and Eder, J. P. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J. Clin. Oncol., 8: 1699–1706, 1990.

    CAS  PubMed  Google Scholar 

  10. Nagasawa, H. T., Elberling, J. A., Good, D. J., and Shirota, F. N. Latent alkyl isocyanates as inhibitors of aldehyde dehydrogenase in vivo. J Med. Chem., 37: 4222–4226, 1994.

    Article  CAS  PubMed  Google Scholar 

  11. Takamizawa, A., Matsumoto, S., Iwata, T., Tochino, Y., Katagiri, K., and Yamaguchi, K. Studies on cyclophosphamide metabolites and their related compounds. II. Preparation of an active species of cyclophosphamide and related compounds. J. Med. Chem., 18: 376–83, 1975.

    Article  CAS  PubMed  Google Scholar 

  12. Bradford, M. A. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal. Biochem., 72: 248–254, 1976.

    Article  CAS  PubMed  Google Scholar 

  13. Yoshida, A., Dave, V., Ward, R. J., and Peters, T. J. Cytosolic aldehyde dehydrogenase (ALDH1) variants found in alcohol flushers. Ann Hum Genet., 53: 1–7, 1989.

    Article  CAS  PubMed  Google Scholar 

  14. Ren, S., Kalhorn, T. F., McDonald, G. B., Anasetti, C., Appelbaum, F. R., and Slattery, J. T. Pharmacokinetics of Cyclophosphamide and its Metabolites in Bone Marrow Transplantation Patients. Clin Pharmacol. Ther., 64: 289–301, 1998.

    Article  CAS  PubMed  Google Scholar 

  15. Segel, I. H. Enzyme Kinetics. New York John Wiley & Sons. 1975.

    Google Scholar 

  16. Ren, S., Kalhorn, T. F., and Slattery, J. T. Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein Drug. Met. Dispos. In press

  17. DeLeve, L. D. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology, 24: 830–837, 1996.

    Article  CAS  PubMed  Google Scholar 

  18. Alarcon, R. A. Studies on the in vivo formation of acrolein: 3-hydroxypropylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation. Cancer Treat. Rep., 60: 327–335, 1976.

    CAS  PubMed  Google Scholar 

  19. Frischer, H. and Ahmad, T. Consequences of erythrocytic glutathione reductase deficiency. J Lab Clin. Med., 109: 583–588. 1987.

    CAS  PubMed  Google Scholar 

  20. Frischer, H., Kennedy, E. J., Chigurupati, R., and Sivarajan, M., Glutathrone, cell proliferation, and 1,3-bis-(2-chloroethyl)-1-nitrosourea in K562 leukemia. J Clin Invest, 92: 2761–2767, 1993.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Chang, T. K. H., Yu, L., Maurel, P., and Waxman, D. J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P.-450 inducers and autoinduction by oxazaphosphorines. Cancer Res, 57: 1946–1954, 1997.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, University of Washington, 98195, Seattle, Washington

    Song Ren

  2. Fred Hutchinson Cancer Research Center, Thomas Building. D2-100; 1100 Fairview Ave. N, 98109-1024, Seattle, Washington, 98109

    John T. Slattery

Authors
  1. Song Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John T. Slattery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John T. Slattery.

Additional information

Published: September 20, 1999.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ren, S., Slattery, J.T. Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine. AAPS PharmSci 1, 14 (1999). https://doi.org/10.1208/ps010314

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/ps010314

Key words

Search

Navigation